featured
SBRT Plus Pembrolizumab and Trametinib vs SBRT Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Stereotactic Body Radiotherapy Plus Pembrolizumab and Trametinib Versus Stereotactic Body Radiotherapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: An Open-Label, Randomised, Controlled, Phase 2 Trial
Lancet Oncol 2021 Jul 05;[EPub Ahead of Print], X Zhu, Y Cao, W Liu, X Ju, X Zhao, L Jiang, Y Ye, G Jin, H ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.